Navigation Links
Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
Date:9/23/2008

r and lead medical negotiator for FDA interactions for AIR(R) Insulin, Lilly's inhaled insulin program.

During its first five years of development, Dr. Muchmore was the sole physician on the Lilly inhaled insulin development effort and the AIR(R) Insulin team. He was responsible for designing and executing all of the early phase studies and he successfully advanced the program to Phase III. Dr. Muchmore's responsibilities at Lilly also included the evaluation of promising new technologies, which is how he became aware of Halozyme's proprietary insulin program and its recombinant human hyaluronidase enzyme technology. Prior to leading Lilly's inhaled insulin program, Dr. Muchmore served on the Evista Product Team for osteoporosis and breast cancer indications from 1995 to 1999 and as its Physician Group Leader from 1997 to 1999. He is the recipient of numerous awards for professional achievement, including the Eli Lilly Global Brand Development Team Leadership Award in 2007.

From 1982 to 1995, Dr. Muchmore was staff endocrinologist at the Scripps Clinic and Research Foundation, holding additional appointments as Clinical Assistant Professor of Medicine, UCSD, and Senior Physician, The Whittier Institute for Diabetes and Endocrinology. Dr. Muchmore also served as visiting endocrinologist at the Logan Heights Community Clinic in San Diego. He received his AB degree in Biological Sciences from Stanford University, his MD from UCSD, and initiated his internship and residency training in internal medicine at the University of Washington Affiliated Hospitals in Seattle, Washington. He finished his residency training in 1978 at the Martinez Veterans Hospital, affiliated with the University of California, Davis. Dr. Muchmore completed a Fellowship in Endocrinology and Metabolism, followed by Instructorship in Medicine, at University Hospital, Seattle in 1982.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
2. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference
3. Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
4. Halozyme Therapeutics Amends Stockholder Rights Plan
5. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
6. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
7. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
8. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
9. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
10. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
11. Halozyme Therapeutics to Present at the Jefferies 2nd Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 16, 2014  LABSCO, the leading specialty sales ... hospitals, physician office laboratories and alternate healthcare settings ... 2014, it will serve as Siemens Healthcare Diagnostics, ... and as a semi-exclusive sales distributor in specified ... United States . LABSCO will be ...
(Date:9/16/2014)... 2014 According to Jeff Howell, Partner ... ITRA Global, new development in Downtown Toronto is expanding ... approving another 755 storeys of new development last week ... will be dominating the Toronto skyline for the foreseeable ... unquenchable thirst for new development. , As the Toronto ...
(Date:9/15/2014)... SYDNEY , Sept. 15, 2014 ... focused on revolutionizing the treatment of cancer through ... cancer cells, announced that, together with the Asbestos ... 2014 Cancer Institute New South Wales (NSW) Premier,s ... other four recipients are the hospitals that will ...
(Date:9/15/2014)... Northeastern University has developed a novel method for ... of nanocarbon structures in carbon nanotube arrays. The ... allow the researchers to tailor the physical properties ... from electronic devices to CNT-reinforced composite materials found ... Their findings were published in the journal ...
Breaking Biology Technology:LABSCO Secures Alliance With Siemens Healthcare Diagnostics 2LABSCO Secures Alliance With Siemens Healthcare Diagnostics 3ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 2ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 3EnGeneIC Named a Recipient of the Cancer Institute NSW Premier's Award for Excellence in Translational Cancer Research 2EnGeneIC Named a Recipient of the Cancer Institute NSW Premier's Award for Excellence in Translational Cancer Research 3Northeastern University Researchers Develop Novel Method for Working with Nanotubes 2
... France, April 23 , - ... Essilor International, the world leader in ophthalmic optics, today,announced ... 31, 2009, representing a reported 10.3% increase on the first ... the period. , Despite contracting demand ...
... RICHMOND, Calif., April 22 Sangamo BioSciences, Inc. (Nasdaq: ... will release its first quarter 2009 financial results on ... press release will be followed by a conference call ... the public via telephone and webcast. During the conference ...
... to Discuss Results to Be Held at 9:00 A.M. - ... VPHM ) first quarter financial results for 2009 are ... the open of the U.S. financial markets.The company will host ... Eastern Time on the same day. During the conference ...
Cached Biology Technology:Essilor : 2009 First Quarter Report 2Essilor : 2009 First Quarter Report 3Essilor : 2009 First Quarter Report 4Sangamo BioSciences Announces First Quarter 2009 Conference Call and Webcast 2Sangamo BioSciences Announces First Quarter 2009 Conference Call and Webcast 3ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009 2
(Date:9/15/2014)... on Earth for the first 500 million years after ... present day, complete with oceans, continents and active crustal ... eon, called the Hadean, has gained substantial new support ... formed more than 4 billion years ago with those ... a possible geological analog for early Earth. , The ...
(Date:9/15/2014)... are hallmarks of the cheetah: The big predator is the ... mph in just a few seconds. As it ramps up ... bounding until it reaches a full gallop. , Now MIT ... implemented in a robotic cheetah a sleek, four-legged assemblage ... much as its feline counterpart. The team recently took the ...
(Date:9/15/2014)... who transplanted combinations of wild, domesticated, and ... to new environments found that within 5 ... foreign genes from wild populations that hybridized ... Applications study provides evidence that natural ... that hybridized populations experience as a result ...
Breaking Biology News(10 mins):Early Earth less hellish than previously thought 2Early Earth less hellish than previously thought 3Run, cheetah, run 2Run, cheetah, run 3
... how the brain controls breathing is fundamental to the ... an automatic rhythmic process that persists without conscious effort ... that has intrigued many scientists for well over 100 ... rhythm throughout life? , Experimental Physiology editor Julian Paton ...
... sudden changes in water quality, creation of coastal "dead ... climate are just some of the potential consequences of ... new United Nations-backed report launched today. , Humans have ... 50 years than in any other period, some 60 ...
... can survive an otherwise lethal dose of vaccinia virus, ... the National Institute of Allergy and Infectious Diseases (NIAID), ... say the investigators, suggest that Gleevec or similar drugs ... smallpox vaccine. The classic smallpox vaccine is made from ...
Cached Biology News:How exactly does the brain control breathing? 2UN: World in big ecological mess 2UN: World in big ecological mess 3Cancer drug slows poxvirus in mice 2Cancer drug slows poxvirus in mice 3
Sheep polyclonal to Melatonin ( Abpromise for all tested applications). Antigen: Melatonin Tg conjugate....
This antibody detects cdc42 on SDS-PAGE immunoblots....
Goat polyclonal to DDDDK tag (FITC) ( Abpromise for all tested applications)....
Rabbit polyclonal to TRPM8 (rating: ****) ( Abpromise for all tested applications). entrezGeneID: 79054 SwissProtID: Q3YFM7...
Biology Products: